No Data
No Data
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. (NASDAQ:INVA), citing the company's unique business model centered around royalties and healthcare assets.The company receives royalties from
ITeos And GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug And Dostarlimab In Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer; Primary Endpoints Of The Trial Are Progression...
ITeos And GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug And Dostarlimab In Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Can
The $3bn Crisis Casting a Shadow Over Dame Emma Walmsley's GSK
CDC 'Preparing for the Possibility' Bird Flu Could Spread More Easily
Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says
Moderna's (MRNA) newly approved respiratory syncytial virus vaccine may achieve stronger than expected US penetration despite entering a market with two seasoned competitors, Oppenheimer said in a Wed
Express News | World Health Organization Chief: At This Time, Who Continues To Assess Risk To Public Health From H5n1 As Low
No Data